Summit Therapeutics (SMMT) Cash from Investing Activities (2019 - 2026)

Summit Therapeutics has reported Cash from Investing Activities for 8 years, with the latest figure at -$238000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 100.15% year-over-year to -$238000.0; the trailing twelve-month figure through Mar 2026 stood at -$334.7 million (down 414.05% YoY), and the FY2025 full-year result was -$174.3 million, up 15.11% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$238000.0, up from -$485.2 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $160.1 million in Q1 2025, with the low at -$645.1 million in Q1 2023.
• Historically, Cash from Investing Activities has averaged -$57.0 million across 5 years, with a median of -$71000.0 in 2025.
• The largest YoY upside for Cash from Investing Activities was 605580.0% in 2023 against a maximum downside of 178587.81% in 2023.
• Summit Therapeutics' Cash from Investing Activities stood at $10000.0 in 2022, then jumped by 605580.0% to $60.6 million in 2023, then soared by 37.83% to $83.5 million in 2024, then tumbled by 681.15% to -$485.2 million in 2025, then surged by 99.95% to -$238000.0 in 2026.
• The last three Cash from Investing Activities figures came in at -$238000.0 (Q1 2026), -$485.2 million (Q4 2025), and -$71000.0 (Q3 2025), per Business Quant data.